Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- University of Alabama at Birmingham
- Study ID
- NCT05632562
- Phase
- EARLY_PHASE1
- Status
- Recruiting
Conditions
- High Grade Glioma
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 89 Years
- Healthy Volunteers
- Not accepted
Interventions
- O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI — DRUGHigh grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
Study Details
This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will undergo simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI) with O-(\[2-\[F-18\]fluoroethyl)-L-tyrosine (FET, amino acid transport) and 1H-1-(3-\[F-18\]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO, hypoxia) at the time of standard of care imaging after completion of RT. The presence of viable tumor at this time point will be assessed on a per patient basis. Study participants will be followed clinically and with standard of care (SOC) imaging for up to 2 years after completion of PET/MRI to determine the nature of lesions seen on investigational imaging and to obtain patient outcome data. The imaging data will also be used to develop a semi-automated workflow suitable for implementation in clinical trials and standard of care PET/MRI studies.
Key Dates
- Start date
- Mar 7, 2024
- Status verified
- Dec 2025
- Primary completion
- Feb 1, 2028
- Completion
- Feb 1, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: PET imaging of system L amino acid transport with FET and hypoxia imaging with FMISOThe participant will have a plastic peripheral intravenous (IV) catheter placed in the arm for Positron emission tomography (PET) tracer and MR contrast administration. FET O-(\[2-\[18F\]fluoroethyl)-L-tyrosine and FMISO 1H-1-(3-\[18F\]fluoro-2-hydroxypropyl)-2-nitroimidazole will be produced by the UAB Cyclotron PET Production Facility. PET/MRI will be performed using a GE Signa PET/MRI system in the AIF with specific imaging protocols for FET and FMISO studies. Upon completion of imaging, the peripheral IV catheter will be removed. The participant will be asked to urinate to reduce bladder dose after completion of each PET acquisition.Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies.
Primary Outcome Measure
Detection of viable glioma based on PET [ Time Frame: Up to 24 months after completing study PET/MRI visits. ]
Central Contacts
- Sebastian M Eady, BS205-996-2636
- Quenteeria S Mooney, BS205-934-3747
Locations (2)
Find similar trials in Birmingham, AL
Related Studies
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsPHASE1 · Recruiting · Pfizer · Birmingham, Alabama
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer CellsPHASE1 · Recruiting · Nationwide Children's Hospital · Columbus, Ohio